Bristol-Myers Squibb
Executive Summary
Signs agreement with the Italian firm Indena to derive anti-cancer agent taxol from needles and twigs of yew tree species in Europe and Asia, the company announces on June 24. Taxol extracted from the bark of Pacific yew trees has shown activity against ovarian and breast cancer. Under the new agreement, Indena, based in Milan, will extract the natural chemical 10-deacetylbaccatin III, a precursor for taxol, from the renewable biomass of yew twigs and needles and export it to the U.S. BMS will then process the natural chemical into taxol through a semi-synthetic method licensed from Florida State University last year. BMS, which plans to file an NDA for natural taxol in the next few months, hopes to file an NDA for this new source in 1993.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth